{"id":26541,"date":"2022-08-22T23:17:00","date_gmt":"2022-08-22T15:17:00","guid":{"rendered":"https:\/\/flcube.com\/?p=26541"},"modified":"2025-02-12T23:20:17","modified_gmt":"2025-02-12T15:20:17","slug":"porton-biologics-completes-rmb-520m-series-b-to-expand-gene-and-cell-therapy-cdmo-platform","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=26541","title":{"rendered":"Porton Biologics Completes RMB 520M Series B to Expand Gene and Cell Therapy CDMO Platform"},"content":{"rendered":"\n

Suzhou Porton Biologics Ltd, a China-based contract development and manufacturing organization (CDMO), announced the completion of a Series B financing round totaling RMB 520 million (USD 76.1 million). The round was led by China Merchants Health Industry Holding Co., Ltd, with participation from CMS Capital, China Merchants Security, Fosun Health Fund, Guangdong Mintou Private Equity Fund, SDIC Taikang Trust, SDIC CMS Management, HM Capital, Huashan Ruilian Fund Management, and MV Venture.<\/p>\n\n\n\n

Funding Details<\/strong>
Proceeds from the Series B round will support Porton’s global expansion, the construction of a commercialization manufacturing plant, and the enhancement of its end-to-end gene and cell therapy (GCT) CDMO platform.<\/p>\n\n\n\n

Company Profile<\/strong>
Founded in 2018, Porton offers a comprehensive GCT CDMO service platform covering plasmids, cell therapy, gene therapy, oncolytic virus, nucleic acid therapy, and live bacterial therapy. The company’s 16,000-square-meter industrialization plant is expected to commence operations in Q4 2023.<\/p>\n\n\n\n

Strategic Outlook<\/strong>
Porton plans to strengthen its capabilities in AAV, oncolytic virus, and mRNA platforms, increase production capacity for GMP plasmid, virus, and cell therapy products, and advance the GCT industry through its enhanced CDMO platform.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Suzhou Porton Biologics Ltd, a China-based contract development and manufacturing organization (CDMO), announced the completion…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[19,20,628],"class_list":["post-26541","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-cro-cmo-cdmo","tag-finance","tag-porton-biologics"],"yoast_head":"\nPorton Biologics Completes RMB 520M Series B to Expand Gene and Cell Therapy CDMO Platform - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Suzhou Porton Biologics Ltd, a China-based contract development and manufacturing organization (CDMO), announced the completion of a Series B financing round totaling RMB 520 million (USD 76.1 million). The round was led by China Merchants Health Industry Holding Co., Ltd, with participation from CMS Capital, China Merchants Security, Fosun Health Fund, Guangdong Mintou Private Equity Fund, SDIC Taikang Trust, SDIC CMS Management, HM Capital, Huashan Ruilian Fund Management, and MV Venture.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=26541\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Porton Biologics Completes RMB 520M Series B to Expand Gene and Cell Therapy CDMO Platform\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=26541\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-22T15:17:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-12T15:20:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=26541#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=26541\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Porton Biologics Completes RMB 520M Series B to Expand Gene and Cell Therapy CDMO Platform\",\"datePublished\":\"2022-08-22T15:17:00+00:00\",\"dateModified\":\"2025-02-12T15:20:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=26541\"},\"wordCount\":198,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"CRO \\\/ CMO \\\/ CDMO\",\"Finance\",\"Porton Biologics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=26541#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=26541\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=26541\",\"name\":\"Porton Biologics Completes RMB 520M Series B to Expand Gene and Cell Therapy CDMO Platform - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-08-22T15:17:00+00:00\",\"dateModified\":\"2025-02-12T15:20:17+00:00\",\"description\":\"Suzhou Porton Biologics Ltd, a China-based contract development and manufacturing organization (CDMO), announced the completion of a Series B financing round totaling RMB 520 million (USD 76.1 million). The round was led by China Merchants Health Industry Holding Co., Ltd, with participation from CMS Capital, China Merchants Security, Fosun Health Fund, Guangdong Mintou Private Equity Fund, SDIC Taikang Trust, SDIC CMS Management, HM Capital, Huashan Ruilian Fund Management, and MV Venture.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=26541#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=26541\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=26541#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Porton Biologics Completes RMB 520M Series B to Expand Gene and Cell Therapy CDMO Platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Porton Biologics Completes RMB 520M Series B to Expand Gene and Cell Therapy CDMO Platform - Insight, China's Pharmaceutical Industry","description":"Suzhou Porton Biologics Ltd, a China-based contract development and manufacturing organization (CDMO), announced the completion of a Series B financing round totaling RMB 520 million (USD 76.1 million). The round was led by China Merchants Health Industry Holding Co., Ltd, with participation from CMS Capital, China Merchants Security, Fosun Health Fund, Guangdong Mintou Private Equity Fund, SDIC Taikang Trust, SDIC CMS Management, HM Capital, Huashan Ruilian Fund Management, and MV Venture.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=26541","og_locale":"en_US","og_type":"article","og_title":"Porton Biologics Completes RMB 520M Series B to Expand Gene and Cell Therapy CDMO Platform","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=26541","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-08-22T15:17:00+00:00","article_modified_time":"2025-02-12T15:20:17+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=26541#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=26541"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Porton Biologics Completes RMB 520M Series B to Expand Gene and Cell Therapy CDMO Platform","datePublished":"2022-08-22T15:17:00+00:00","dateModified":"2025-02-12T15:20:17+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=26541"},"wordCount":198,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["CRO \/ CMO \/ CDMO","Finance","Porton Biologics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=26541#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=26541","url":"https:\/\/flcube.com\/?p=26541","name":"Porton Biologics Completes RMB 520M Series B to Expand Gene and Cell Therapy CDMO Platform - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-08-22T15:17:00+00:00","dateModified":"2025-02-12T15:20:17+00:00","description":"Suzhou Porton Biologics Ltd, a China-based contract development and manufacturing organization (CDMO), announced the completion of a Series B financing round totaling RMB 520 million (USD 76.1 million). The round was led by China Merchants Health Industry Holding Co., Ltd, with participation from CMS Capital, China Merchants Security, Fosun Health Fund, Guangdong Mintou Private Equity Fund, SDIC Taikang Trust, SDIC CMS Management, HM Capital, Huashan Ruilian Fund Management, and MV Venture.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=26541#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=26541"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=26541#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Porton Biologics Completes RMB 520M Series B to Expand Gene and Cell Therapy CDMO Platform"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/26541","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=26541"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/26541\/revisions"}],"predecessor-version":[{"id":26542,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/26541\/revisions\/26542"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=26541"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=26541"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=26541"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}